Smac mimetics and TNFalpha: a dangerous liaison?

Hao Wu1, Jurg Tschopp, Su-Chang Lin

  • 1Department of Biochemistry, Weill Medical College of Cornell University, New York, NY 10021, USA. haowu@med.cornell.edu

Cell
|November 21, 2007
PubMed

Insights

Small-molecule Smac mimetics kill cancer cells by inducing self-degradation of inhibitor of apoptosis proteins (IAPs). This process leads to tumor necrosis factor-alpha (TNFα)-mediated cell death, revealing a novel therapeutic mechanism.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Pathways

Background:

  • Inhibitor of apoptosis proteins (IAPs) like XIAP, cIAP1, and cIAP2 are frequently overexpressed in cancer cells.
  • IAPs play a crucial role in preventing programmed cell death (apoptosis).
  • Small-molecule Smac mimetics were hypothesized to enhance apoptosis by promoting caspase activation.

Purpose of the Study:

  • To investigate the precise mechanism by which Smac mimetics induce cancer cell death.
  • To elucidate the role of IAPs in the cellular response to Smac mimetics.
  • To identify alternative pathways for cancer therapy targeting IAPs.

Main Methods:

  • Utilized Smac mimetic compounds in cancer cell models.
  • Analyzed protein degradation pathways, focusing on cIAPs.
  • Investigated the involvement of TNFα signaling in cell death induction.

Main Results:

  • Smac mimetics primarily induce autoubiquitination and subsequent degradation of cIAP1 and cIAP2.
  • This degradation event is the main driver of cancer cell death, not direct caspase activation.
  • The process culminates in TNFα-mediated necroptosis, a form of inflammatory cell death.

Conclusions:

  • Smac mimetics represent a novel class of anti-cancer agents targeting IAP degradation.
  • The primary mechanism involves cIAP depletion, leading to TNFα-induced cell death.
  • These findings offer new therapeutic strategies for cancers with upregulated IAPs.